Platelet rich plasma and hyaluronic acid in shoulder tendon injuries
- Conditions
- Shoulder injuriesRotator cuff syndrome
- Registration Number
- RBR-105wyncc
- Lead Sponsor
- Prevent Senior
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Adults aged between 40 and 85 years, regardless of gender; clinical and radiological diagnosis of tendinopathy or partial bursal lesions <50% of the supra and infraspinatus thickness; availability of follow-up during the study period; provided voluntary written consent to participate in the study, confirmed by signing the informed consent form
Having other joint diseases or joint trauma, autoimmune diseases or intra-articular medication in the last 12 months; history of acute or chronic communicable diseases, including hepatitis B, hepatitis C and HIV; history of systemic bone or cartilaginous disorders; evidence of active infection or history of infection in the joint to be infiltrated in this study; comorbidity that the physician considers as a contraindication for the infiltration of platelet-rich plasma; chronic treatment with anticoagulant or immunosuppressive drugs; previous surgery (at any time) of the affected shoulder; presence of at least one of the following diseases: adhesive capsulitis, calcareous tendonitis, glenohumeral arthrosis or acromioclavicular joint disease
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method SPADI - An improvement in the scores of this questionnaire is expected in patients undergoing treatment with Platelet Rich Plasma and with Hyaluronic Acid than in the control group.;Quick-DASH - An improvement in the scores of this questionnaire is expected in patients undergoing treatment with Platelet Rich Plasma and with Hyaluronic Acid than in the control group.;VSA (Visual Scale Analogic of Pain) - A lower value is expected in patients treated with Platelet Rich Plasma and with Hyaluronic Acid than in the control group.
- Secondary Outcome Measures
Name Time Method Secondary outcomes are not expected